In the BioHarmony Drug Report Database
Midamor (amiloride) is a small molecule pharmaceutical. Amiloride was first approved as Midamor on 1982-01-01. It is used to treat ascites, cystic fibrosis, edema, heart failure, and hypertension amongst others in the USA. It is known to target acid-sensing ion channel 2, acid-sensing ion channel 1, transient receptor potential cation channel subfamily V member 2, sodium/hydrogen exchanger 5, acid-sensing ion channel 3, short transient receptor potential channel 6, transient receptor potential cation channel subfamily A member 1, polycystic kidney disease 2-like 1 protein, short transient receptor potential channel 7, gonadotropin-releasing hormone receptor, alpha-2A adrenergic receptor, sodium/hydrogen exchanger 2, sodium/hydrogen exchanger 3, sodium/hydrogen exchanger 1, and urokinase-type plasminogen activator.
Image (chem structure or protein)